S.v. N.SönmezA new era? Biocon is stepping into India's generic GLP‑1 market, aiming for affordable diabetes and weight‑loss solutions. CEO Tambe reports strong earnings growth, hinting at a future shift in metabolic care. What does this mean for patients?
A new era? Biocon is stepping into India's generic GLP‑1 market, aiming for affordable diabetes and weight‑loss solutions. CEO Tambe reports strong earnings growth, hinting at a future shift in metabolic care. What does this mean for patients?